Concepedia

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Arndt Vogel, Andrés Cervantes, Ian Chau, Bruno Daniele, Josep M. Llovet, Tim Meyer, Ulf P. Neumann, Jens Ricke, Bruno Sangro, Peter Schirmacher,

Annals of Oncology · 2018 · 1.1K citations · 104 references

DOIFull text

Open access

Concepts

Abstract

DO NOT RECLAIM. These records were duplicates in PubMed and have been removed in PubMed. The data of this publication is already in Lirias on this page: https://lirias2.kuleuven.be/viewobject.html?cid=1&id=2295592

References

104

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

Jacques Ferlay, Isabelle Soerjomataram, Rajesh Dikshit et al. · International Journal of Cancer · 2014 · 29K citations · Full text

, , +16

Sorafenib in Advanced Hepatocellular Carcinoma

Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro et al. · New England Journal of Medicine · 2008 · 13K citations · Full text

, , +12

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen et al. · The Lancet Oncology · 2008 · 5.8K citations

, , +11

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo, Richard S. Finn, Shukui Qin et al. · The Lancet · 2018 · 5.4K citations · Full text

, , +12

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau et al. · The Lancet · 2017 · 4.3K citations · Full text

, , +13